Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hepatol Commun. 2024 Oct 30;8(11). doi: 10.1097/HC9.0000000000000571. eCollection 2024 Nov 1.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting >30% of the global population. Metabolic dysregulation, particularly insulin resistance and its subsequent manifestation as type 2 diabetes mellitus, serves as the fundamental pathogenesis of metabolic liver disease. Clinical evidence of the recent nomenclature evolution is accumulating. The interaction and impacts are bidirectional between MASLD and diabetes in terms of disease course, risk, and prognosis. Therefore, there is an urgent need to highlight the multifaceted links between MASLD and diabetes for both hepatologists and diabetologists. The surveillance strategy, risk stratification of management, and current therapeutic achievements of metabolic liver disease remain the major pillars in a clinical care setting. Therefore, the Taiwan Association for the Study of the Liver (TASL), Taiwanese Association of Diabetes Educators, and Diabetes Association of the Republic of China (Taiwan) collaboratively completed the first guidance in patients with diabetes and MASLD, which provides practical recommendations for patient care.
代谢相关脂肪性肝病（MAFLD）是全球最常见的慢性肝病，影响全球 30%以上的人口。代谢失调，特别是胰岛素抵抗及其随后表现为 2 型糖尿病，是代谢性肝病的基本发病机制。最近命名演变的临床证据正在积累。在疾病过程、风险和预后方面，MAFLD 和糖尿病之间存在双向相互作用和影响。因此，迫切需要突出 MAFLD 和糖尿病之间的多方面联系，这对肝病学家和糖尿病学家都很重要。代谢性肝病的监测策略、管理风险分层和当前的治疗成就仍然是临床治疗中的主要支柱。因此，台湾肝病研究学会（TASL）、台湾糖尿病教育者协会和中华民国糖尿病协会（台湾）共同完成了糖尿病和 MAFLD 患者的第一份指南，为患者护理提供了实用建议。
